Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. more
Time Frame | SAGE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.61% | 0.49% | -1.93% |
1-Month Return | -0.36% | -3.1% | -3.69% |
3-Month Return | -12.87% | -8.59% | 0.82% |
6-Month Return | -49.68% | -4.57% | 3.51% |
1-Year Return | -78.15% | -0.94% | 21.91% |
3-Year Return | -86.84% | 2.88% | 24.73% |
5-Year Return | -92.81% | 35.84% | 78.4% |
10-Year Return | -87.33% | 98.8% | 187.28% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 6.87M | 1.11B | 6.31M | 7.69M | 86.45M | [{"date":"2019-12-31","value":0.62,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.57,"profit":true},{"date":"2022-12-31","value":0.69,"profit":true},{"date":"2023-12-31","value":7.76,"profit":true}] |
Cost of Revenue | 400.00K | 565.00K | 553.00K | 813.00K | 2.16M | [{"date":"2019-12-31","value":18.53,"profit":true},{"date":"2020-12-31","value":26.17,"profit":true},{"date":"2021-12-31","value":25.61,"profit":true},{"date":"2022-12-31","value":37.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 6.47M | 1.11B | 5.75M | 6.87M | 84.30M | [{"date":"2019-12-31","value":0.58,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.52,"profit":true},{"date":"2022-12-31","value":0.62,"profit":true},{"date":"2023-12-31","value":7.57,"profit":true}] |
Gross Margin | 94.18% | 99.95% | 91.23% | 89.42% | 97.50% | [{"date":"2019-12-31","value":94.22,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.28,"profit":true},{"date":"2022-12-31","value":89.47,"profit":true},{"date":"2023-12-31","value":97.55,"profit":true}] |
Operating Expenses | 714.59M | 489.67M | 466.66M | 553.86M | 630.76M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":68.52,"profit":true},{"date":"2021-12-31","value":65.3,"profit":true},{"date":"2022-12-31","value":77.51,"profit":true},{"date":"2023-12-31","value":88.27,"profit":true}] |
Operating Income | (708.12M) | 596.23M | (460.91M) | (546.99M) | (579.85M) | [{"date":"2019-12-31","value":-118.77,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-77.3,"profit":false},{"date":"2022-12-31","value":-91.74,"profit":false},{"date":"2023-12-31","value":-97.25,"profit":false}] |
Total Non-Operating Income/Expense | 55.69M | 19.44M | 5.90M | 28.39M | 74.43M | [{"date":"2019-12-31","value":74.82,"profit":true},{"date":"2020-12-31","value":26.12,"profit":true},{"date":"2021-12-31","value":7.93,"profit":true},{"date":"2022-12-31","value":38.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (680.24M) | 606.07M | (457.89M) | (532.78M) | (541.49M) | [{"date":"2019-12-31","value":-112.24,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-75.55,"profit":false},{"date":"2022-12-31","value":-87.91,"profit":false},{"date":"2023-12-31","value":-89.34,"profit":false}] |
Income Taxes | (30.09M) | 15.52M | (7.07M) | (29.52M) | (5.36M) | [{"date":"2019-12-31","value":-193.91,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-45.53,"profit":false},{"date":"2022-12-31","value":-190.24,"profit":false},{"date":"2023-12-31","value":-34.53,"profit":false}] |
Income After Taxes | (650.15M) | 590.56M | (450.83M) | (503.27M) | (536.13M) | [{"date":"2019-12-31","value":-110.09,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-76.34,"profit":false},{"date":"2022-12-31","value":-85.22,"profit":false},{"date":"2023-12-31","value":-90.78,"profit":false}] |
Income From Continuous Operations | (680.24M) | 606.07M | (457.89M) | (532.78M) | (655.93M) | [{"date":"2019-12-31","value":-112.24,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-75.55,"profit":false},{"date":"2022-12-31","value":-87.91,"profit":false},{"date":"2023-12-31","value":-108.23,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (650.15M) | 606.07M | (450.83M) | (503.27M) | (541.49M) | [{"date":"2019-12-31","value":-107.27,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-74.38,"profit":false},{"date":"2022-12-31","value":-83.04,"profit":false},{"date":"2023-12-31","value":-89.34,"profit":false}] |
EPS (Diluted) | (13.38) | 11.64 | (7.80) | (8.98) | (10.31) | [{"date":"2019-12-31","value":-114.95,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-67.01,"profit":false},{"date":"2022-12-31","value":-77.15,"profit":false},{"date":"2023-12-31","value":-88.57,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SAGE | |
---|---|
Cash Ratio | 9.42 |
Current Ratio | 10.02 |
Quick Ratio | 10.31 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SAGE | |
---|---|
ROA (LTM) | -29.62% |
ROE (LTM) | -49.34% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SAGE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.89 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SAGE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 3.19 |
P/B | 0.62 |
Price/FCF | NM |
EV/R | 2.10 |
EV/Ebitda | NM |
PEG | 0.74 |
Sage Therapeutic (SAGE) share price today is $7.696
Yes, Indians can buy shares of Sage Therapeutic (SAGE) on Vested. To buy Sage Therapeutic from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SAGE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Sage Therapeutic (SAGE) via the Vested app. You can start investing in Sage Therapeutic (SAGE) with a minimum investment of $1.
You can invest in shares of Sage Therapeutic (SAGE) via Vested in three simple steps:
The 52-week high price of Sage Therapeutic (SAGE) is $27.68. The 52-week low price of Sage Therapeutic (SAGE) is $4.62.
The price-to-earnings (P/E) ratio of Sage Therapeutic (SAGE) is
The price-to-book (P/B) ratio of Sage Therapeutic (SAGE) is 0.62
The dividend yield of Sage Therapeutic (SAGE) is 0.00%
The market capitalization of Sage Therapeutic (SAGE) is $458.80M
The stock symbol (or ticker) of Sage Therapeutic is SAGE